艾普奈珠单抗(Eptinezumab-JJMR) - 药物靶点：CGRP_在研适应症：偏头痛，丛集性头痛_专利_临床

概要

基本信息

药物类型

单克隆抗体

别名

Eptinezumab、ALD-403、LU AG09221

+ [1]

靶点

CGRP

作用机制

CGRP拮抗剂(降钙素基因相关肽拮抗剂)

治疗领域

在研适应症

非在研适应症

原研机构

在研机构

Lundbeck Seattle BioPharmaceuticals, Inc.Lundbeck Australia Pty Ltd.

+ [1]

非在研机构-

最高研发阶段批准上市

首次获批日期

美国 (2020-02-21),

偏头痛

最高研发阶段(中国)临床3期

特殊审评-

登录后查看时间轴

结构/序列

Sequence Code 156338

来源: *****

Sequence Code 201708H

来源: *****

关联

41

项与艾普奈珠单抗相关的临床试验

NCT05937152

/ Recruiting临床2期IIT

CAT-Trial: CGRP Monoclonal Antibody for Treatment of Painful Diabetic Neuropathy: a Double-blind, Randomized, Placebo-controlled, International Multicenter, Phase II Clinical Trial

The main purpose of this study is to compare the change in pain intensity during treatment with a CGRP monoclonal antibody (eptinezumab) compared with placebo treatment in patients with painful diabetic polyneuropathy (DPN).

开始日期2025-01-01

申办/合作机构

Mayo Clinic

NCT06701526

/ Recruiting临床4期

Interventional, Open-label Trial, Investigating the Effectiveness of Eptinezumab in Participants With Migraine and Previous Inadequate Response to CGRP-targeting Therapies

The main goal of this trial is to learn whether eptinezumab improves migraine symptoms and quality of life of participants with migraine who did not perceive a sufficient improvement during previous treatment with therapies targeting calcitonin gene-related peptide (CGRP).

开始日期2024-12-18

申办/合作机构

H. Lundbeck A/S

NCT06628921

/ Not yet recruitingN/A

The Effectiveness of Eptinezumab During a Migraine Attack (the BE-FREE Study): a TACHIS Sub-study

A perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. During the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. This finding is known in the literature, having been described in the RELIEF study. This study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved.
The study includes all patients who will begin treatment according to clinical practice, and are included in the TACHIS study (NCT06409845, Unique protocol ID RICe_5)

开始日期2024-10-30

申办/合作机构

University of Florence

[+1]

100 项与艾普奈珠单抗相关的临床结果

登录后查看更多信息

100 项与艾普奈珠单抗相关的转化医学

登录后查看更多信息

100 项与艾普奈珠单抗相关的专利（医药）

登录后查看更多信息

207

项与艾普奈珠单抗相关的文献（医药）

2025-02-01·HEADACHE

Pharmacological differences and switching among anti‐CGRP monoclonal antibodies: A narrative review

Review

作者: Romozzi, Marina ; Vigani, Giulia ; Rivi, Veronica ; Raffaelli, Bianca ; Burgalassi, Andrea ; Iannone, Luigi Francesco ; Calabresi, Paolo ; Guerzoni, Simona ; Munafò, Antonio ; De Cesaris, Francesco ; Altamura, Claudia

Abstract:

Antibodies targeting either the calcitonin gene–related peptide (CGRP), such as galcanezumab, fremanezumab, and eptinezumab, or the receptor (erenumab) have been approved for the prevention of episodic and chronic migraine. Although widely used and generally effective, a proportion of patients discontinue treatment due to lack of efficacy. In both randomized controlled trials and observational studies, all anti‐CGRP monoclonal antibodies (mAbs) have consistently demonstrated comparable efficacy and tolerability, suggesting a pharmacological class effect. However, differences in therapeutic targets, structure, and pharmacokinetic characteristics may influence their efficacy and safety differently. Therefore, in patients not achieving a clinically meaningful response with one anti‐CGRP antibody, switching to a different antibody may be a viable option. This review examines the pharmacological characteristics and distinctions among anti‐CGRP mAbs, highlighting their mechanisms of action and pharmacokinetic profiles, along with the clinical observational data of switching. Finally, we summarize suggestions from international guidelines.

2025-01-01·JOURNAL OF NEUROLOGY

Eptinezumab treatment was associated with longer interictal headache/migraine periods which corresponded to greater improvements in patient-reported quality of life measures

Article

作者: Asher, Divya ; Tepper, Stewart J ; Cady, Roger ; Hirman, Joe ; Fiore, Damian ; Diamond, Merle L

Abstract:

Introduction:

Longer periods between headache episodes (interictal periods) may provide greater time for the nervous system to reset from a previous episode, potentially improving disease status and health-related quality of life. This post hoc analysis evaluated this hypothesis by associating patients’ longest interictal periods with improvements in patient-reported outcomes.

Methods:

PROMISE-2 (NCT02974153) was a double-blind, placebo-controlled study evaluating eptinezumab for preventive treatment of chronic migraine (N = 1072). Daily electronic diary data from Weeks 1–12 and Weeks 1–24 were used to identify interictal periods, defined as days between headache episodes. For each patient, the longest interictal period within these intervals was identified and categorized (1–4, 5–9, 10–14, > 14, and > 21 days). For each category, the following patient-reported outcomes were assessed: 6-item Headache Impact Test (HIT-6), Patient Global Impression of Change (PGIC), and patient-identified most bothersome symptom (PI-MBS).

Results:

Excluding interictal periods with > 10% missing data (resulting in 1010 patients with sufficient data), the mean (SD) of longest interictal periods over Weeks 1–12 was 9.4 (11.0) days. A ≥6-point HIT-6 reduction was observed in 78% (56/72) vs 26% (91/351) of patients with a > 21-day vs 1–4-day longest interictal period, respectively; much or very much improvement per PGIC was reported in 90% (65/72) vs 25% (87/348), respectively, and per PI-MBS was reported in 88% (63/72) vs 26% (92/348), respectively. Similar results were observed for Weeks 1–24.

Conclusion:

Longer interictal periods were associated with more patients indicating positive changes in headache-related life impact, disease status, and symptomology.Trial registration: ClinicalTrials.gov (identifier: NCT02974153; registered: 2016-11-23)

2025-01-01·HEADACHE

Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial

Article

作者: Ettrup, Anders ; Sperling, Bjørn ; Boserup, Line Pickering ; Ranc, Kristina ; Gryglas‐Dworak, Anna ; Josiassen, Mette Krog ; Schim, Jack ; Ashina, Messoud

Abstract:

Objective:

To evaluate long‐term reductions in acute headache medication (AHM) use with eptinezumab versus placebo in patients with prior preventive migraine treatment failures and medication overuse (MO).

Background:

Preventive migraine treatment is recommended for patients for whom AHMs have failed and for those who are using excessive amounts of AHM. MO may worsen headache and migraine symptoms in people with migraine; it is a risk factor for disease chronification and/or MO headache.

Methods:

DELIVER was a multicenter, parallel‐group, double‐blind, randomized, placebo‐controlled, phase 3b clinical trial that randomized adults with migraine and two to four prior preventive failures to eptinezumab 100 mg, 300 mg, or placebo infusion every 12 weeks; patients initially given placebo received eptinezumab 100 mg or 300 mg in the extension period. MO was defined according to diagnostic criteria for MO headache in the baseline diary reports. This post hoc analysis of the DELIVER study included change from baseline in AHM days/month of use (ergotamines, triptans, simple or combination analgesics, and opioids; total and select class‐specific use) in the MO population.

Results:

A total of 890 patients were included in the total population, and 438/890 (49.2%) had MO at baseline. In both the total population and MO population, eptinezumab resulted in greater reductions in total AHM days/month of use during weeks 1–24 than placebo, with triptans showing the largest reduction among AHM classes. Patients switching from placebo to eptinezumab experienced reductions in AHM days/month similar to that of initial eptinezumab treatment. In the extension population, mean (standard error [SE]) changes from baseline in AHM days/month were −4.6 (0.32; 100 mg) and −4.8 (0.32; 300 mg) across weeks 1–4 in patients who received eptinezumab for the entire treatment period and were −4.8 (0.44; placebo–100 mg) and −5.5 (0.44; placebo–300 mg) across weeks 25–28 in patients who switched from placebo to eptinezumab. Mean (SE) changes from baseline in AHM days/month in the extension MO population were −6.5 (0.59; 100 mg) and −6.6 (0.57; 300 mg) across weeks 1–4 in patients who received eptinezumab for the entire treatment period and were −7.1 (0.81; 100 mg) and −8.0 (0.80; 300 mg) across weeks 25–28 in patients who were switched from placebo to eptinezumab. All treatment arms sustained or further reduced AHM use across 18 months of trial participation. Across weeks 1–4, in patients fulfilling criteria for MO at baseline, 68.0% (102/150) of patients treated with eptinezumab 100 mg and 74.7% (109/146) of patients treated with eptinezumab 300 mg reported AHM use below MO thresholds compared to 43.3% (61/141) of patients receiving placebo. In patients with MO at baseline, the proportion of patients without MO remained above 60.0% for all treatment groups during the extension period.

Conclusions:

Eptinezumab reduced total AHM use more than placebo in patients with prior preventive failures and in patients with MO at baseline; largest reductions were observed for triptans. Robust reductions in AHM use after eptinezumab were sustained or further reduced with up to 18 months of treatment, and most patients no longer met thresholds for MO.

52

项与艾普奈珠单抗相关的新闻（医药）

2024-12-02

·蒲公英Ouryao

最新粤港澳大湾区内地九市临床急需进口港澳药品医疗器械目录

转自：广东省药监局编辑：水晶 12月2日，广东省药监局网省消息，广东省药监局和广东省卫健委发布粤港澳大湾区内地九市临床急需进口港澳药品医疗器械目录（2024年）的通告。《通告》指出，本批目录收录34个上市药品及37个医疗器械。对已列入目录的药械产品，将于2024年12月1日起按照《条例》第九条进行管理。 34个药品：卡那奴单抗、维莫德吉胶囊、盐酸维那卡兰注射液、阿仑珠单抗、罗氟司特片、氨己烯酸薄膜衣片、卡博替尼薄膜衣片、阿培利司薄膜衣片、厄达替尼片、注射用羟钴胺素、布西珠单抗、伊匹木单抗注射液、巴氯芬注射液、艾沙妥昔单抗注射用浓缩液、肾上腺素注射液（预充笔）、莱博雷生片、瑞玛奈珠单抗、硫酸瑞美吉泮口崩片、注射用坦昔妥单抗、二十碳五烯酸乙酯软胶囊、阿扎胞苷片、曲美木单抗、注射用芦比替定、阿司福酶α注射液、阿伏利尤单抗、特泽利尤单抗、磷酸芦可替尼乳膏、罗莫佐单抗、重组人促卵泡素α/促黄体素α注射液、注射用重组人促卵泡素α/促黄体素α、艾普奈珠单抗、伊曲莫德片、依洛硫酸酯酶α注射液、维替索妥尤单抗。根据《广东省粤港澳大湾区内地九市进口港澳药品医疗器械管理条例》（以下简称《条例》）中对急需港澳药械实施目录管理的要求，广东省药品监督管理局、广东省卫生健康委员会经研究决定发布广东省粤港澳大湾区内地九市临床急需港澳药品医疗器械目录（2024年）。本批目录将按《国家药品监督管理局国家卫生健康委员会关于临床急需境外新药审评审批相关事宜的公告》（2018年第79号）发布并符合《条例》要求的港澳已上市药品及《条例》实施前已批准的共71个药品及医疗器械收录。对已列入目录的药械产品，将于2024年12月1日起按照《条例》第九条进行管理。特此通告。附件：1.广东省粤港澳大湾区内地九市临床急需进口港澳药品目录（2024年） 2.广东省粤港澳大湾区内地九市临床急需进口港澳医疗器械目录（2024年）广东省药品监督管理局广东省卫生健康委员会 2024年11月29日

2024-10-24

·GBIHealth

斥资13.3亿！默沙东收购新型肿瘤疗法开发商Modifi Biosciences

药械追踪 No.1 / 礼来阿尔茨海默病疗法多纳单抗在英国获批上市 2024年10月23日，礼来（NYS：LLY）宣布，英国药品和保健产品监管局（MHRA）已授予多纳单抗（donanemab）上市许可，每四周静注一次用于治疗英国符合条件的成年人因阿尔茨海默病引起的轻度认知障碍和轻度痴呆。多纳单抗是继渤健和卫材的阿杜卡单抗（aducanumab）（现已撤市）以及卫材的乐意保（仑卡奈单抗）之后，第三种获得全球批准的抗淀粉样蛋白AD疗法。2024年7月，多纳单抗在美国获批上市，9月在日本获批上市。在中国，礼来公司于2023年10月提交了多纳单抗的上市申请，并于当年11月获得优先审评资格，目前仍在审评中。 ->点击文末阅读原文，解锁完整双语新闻 No.2/ 灵北偏头痛疗法艾普奈珠单抗落地粤港澳大湾区 2024年10月23日，灵北旗下预防性治疗成人偏头痛的创新药物艾普奈珠单抗（Eptinezumab）通过“港澳药械通”正式落地粤港澳大湾区中山大学孙逸仙纪念医院。艾普奈珠单抗已于2020年2月获美国FDA批准，适用于成人偏头痛的预防性治疗，这也是FDA批准的首个也是唯一经静脉注射使用的偏头痛预防性治疗的靶向CGRP的单克隆抗体类药物。2022年11月，艾普奈珠单抗落地海南博鳌乐城先行区。 ->点击文末阅读原文，解锁完整双语新闻企业动态 No.1 / 默沙东斥资13.3亿美元收购新型肿瘤疗法开发商Modifi Biosciences 2024年10月23日，默沙东宣布收购Modifi Biosciences，获得其基于DNA修复缺陷治疗难治肿瘤的临床前分子。此次收购包括3000万美元的预付款和总计13亿美元的潜在分期付款。 Modifi Biosciences成立于2021年，致力于开发通过DNA修饰治疗肿瘤的新型药物。该公司基于从耶鲁大学获得的技术开发了一类新型小分子，针对缺乏关键DNA修复蛋白O6-甲基鸟嘌呤-DNA甲基转移酶（MGMT）的肿瘤细胞。 ->点击文末阅读原文，解锁完整双语新闻全球医疗情报领导者解锁隐藏在数据中的商业潜力关于 G B I ” 自从2002年成立以来，GBI始终以技术为驱动，为药企、器械及行业相关服务商提供贯穿生命周期的全球药品市场竞争数据、全球行业资讯、HCPs洞察、全国医疗器械数据等商业信息与洞察，助力企业在进行战略布局和决策时，脱颖而出。历经20余年的深耕细作GBI已成为95%以上跨国药企、国内头部药企、咨询与投资机构等医疗圈灯塔用户值得信赖的长期合作伙伴。联系我们投稿 | 发稿 | 媒体合作 ▶ zhangxinyue13@baidu.com 数据库 | 咨询服务 | 资讯追踪 ▶ 点击左下“阅读原文”完成表单填写点击阅读原文，解锁完整双语新闻

并购优先审批申请上市

2024-10-14

·EndPoints

Lundbeck makes $2.6B cash move for Longboard a month after starting Phase 3 in Dravet syndrome

Danish drugmaker Lundbeck will buy La Jolla, CA-based Longboard Pharmaceuticals for $2.6 billion in cash, the companies said Monday morning, marking the largest biopharma M&A deal since July . Neuroscience-focused Lundbeck will get access to a 5-HT2C superagonist that just entered Phase 3 last month for Dravet syndrome, a severe type of epilepsy found in infancy. The experimental medicine, known as bexicaserin, could also apply to other developmental and epileptic encephalopathies like Lennox-Gastaut syndrome and CDKL5 deficiency disorder, the company has said. Lundbeck projects a launch of bexicaserin in the last quarter of 2028 and global peak sales potential of up to $2 billion. The drugmaker also gets an S1P receptor modulator dubbed LP659 that is in Phase 1 and could be tested in multiple neurological diseases. Lundbeck CEO Charl van Zyl said Longboard will “become a cornerstone in Lundbeck’s neuro-rare franchise.” “Bexicaserin addresses a critical unmet need for patients suffering from rare and severe epilepsies, for which there are very few good treatment options available,” van Zyl said in a statement. Longboard spun out of Arena Pharmaceuticals with $56 million in October 2020. It went public five months later. Pfizer then bought Arena for $6.7 billion in December 2021. The deal comes amid a relatively dull past few months for public biopharma M&A, with many of the recent deals falling below $1.3 billion. There has been no deal of $5 billion or higher yet in 2024. Lundbeck itself has been relatively quiet on the acquisition front since its $1.95 billion Alder BioPharmaceuticals deal in September 2019. That led to a migraine drug approval a few months later for Vyepti . The Longboard deal is slated to close this quarter, and both boards have approved it, the companies said. Longboard will be bought for $60 per share $LBPH . Its share price skyrocketed 50% to $58 in premarket trading.

并购上市批准临床3期临床1期

100 项与艾普奈珠单抗相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	艾普奈珠单抗	L01XC	DB14040

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Lundbeck Seattle BioPharmaceuticals, Inc.	2020-02-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
药物引起的头痛	临床3期	格鲁吉亚	H. Lundbeck A/S	2021-02-17
药物引起的头痛	临床3期	韩国	H. Lundbeck A/S	2021-02-17
药物引起的头痛	临床3期	西班牙	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	中国	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	格鲁吉亚	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	韩国	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	西班牙	H. Lundbeck A/S	2021-02-17
继发性头痛症	临床3期	中国台湾	H. Lundbeck A/S	2021-02-17
丛集性头痛	临床3期	美国	H. Lundbeck A/S	2020-12-23
丛集性头痛	临床3期	日本	H. Lundbeck A/S	2020-12-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02974153 (PROMISE-2, Pubmed \| J Neurol)	临床3期	偏头痛 \| 头痛	1,072	Eptinezumab	鹹鏇範選糧鏇觸選觸醖(壓衊鏇蓋範簾顧衊鑰淵) = 獵衊製醖鬱鬱齋夢獵積範夢壓網範醖選膚網齋 (淵鬱憲衊簾鬱範簾壓壓 ) 更多	-	2025-01-01
				Placebo	鹹鏇範選糧鏇觸選觸醖(壓衊鏇蓋範簾顧衊鑰淵) = 齋膚夢醖構遞簾蓋遞壓範夢壓網範醖選膚網齋 (淵鬱憲衊簾鬱範簾壓壓 ) 更多
NCT04688775 (ALLEVIATE, CTgov)	临床3期	丛集性头痛	231	Eptinezumab (Eptinezumab)	顧築獵襯窪鬱膚廠膚獵(觸艱繭簾築願窪夢選鏇) = 簾遞鏇醖衊鬱壓築範鹽鑰遞簾艱淵餘廠顧鑰鹽 (襯積願願選顧願夢窪鑰, 夢觸構構積夢襯醖簾艱 ~ 願顧醖鬱網鬱鬱網夢蓋) 更多	-	2024-08-09
				placebo+eptinezumab (Placebo)	顧築獵襯窪鬱膚廠膚獵(觸艱繭簾築願窪夢選鏇) = 鏇獵憲顧蓋積淵夢壓廠鑰遞簾艱淵餘廠顧鑰鹽 (襯積願願選顧願夢窪鑰, 淵淵鑰鬱襯製壓鬱窪壓 ~ 構製鏇網構觸鬱餘鬱繭) 更多
NCT05064397 (CHRONICLE, CTgov)	临床3期	丛集性头痛	131	Eptinezumab	鏇範艱構鏇鬱餘廠淵繭(醖鏇願艱積遞製齋繭構) = 願鹹艱淵憲簾餘鹹淵簾襯淵糧艱鑰鏇遞積鹹簾 (獵鑰構構壓積鬱窪糧顧, 觸範衊選壓積鏇廠鏇艱 ~ 夢壓製積願膚觸鹽膚壓) 更多	-	2024-08-06
NCT05284019 (EVEC, CTgov)	临床4期	偏头痛	32	Onabotulinumtoxin-A (Onabotulinumtoxin-A)	夢繭襯簾壓衊糧築餘構(積觸壓蓋衊願製齋範範) = 膚夢顧壓顧壓夢鹹膚蓋襯壓淵顧醖網廠鑰鹽齋 (鬱淵壓衊衊壓觸糧膚糧, 鬱醖餘壓襯願蓋衊範窪 ~ 壓遞鏇襯糧鹹壓淵選襯) 更多	-	2024-05-29
				Eptinezumab (Eptinezumab)	夢繭襯簾壓衊糧築餘構(積觸壓蓋衊願製齋範範) = 鑰鹽壓選壓衊糧鬱鬱鬱襯壓淵顧醖網廠鑰鹽齋 (鬱淵壓衊衊壓觸糧膚糧, 餘願餘餘糧壓築鑰憲鏇 ~ 壓簾衊製鹹願鑰鑰構選) 更多
REVIEW (AAN2024)	N/A	偏头痛	94	Eptinezumab (Patients with psychiatric conditions)	糧鬱範鏇餘醖鬱鹽構網(艱選淵淵壓鬱淵遞夢壓) = 憲廠製淵築鬱繭壓鬱範獵構網糧積醖艱廠鬱築 (襯鹹鬱蓋顧積鬱窪憲窪 ) 更多	积极	2024-04-09
				Eptinezumab (Patients without psychiatric conditions)	糧鬱範鏇餘醖鬱鹽構網(艱選淵淵壓鬱淵遞夢壓) = 鏇壓醖鏇鏇製鏇憲齋壓獵構網糧積醖艱廠鬱築 (襯鹹鬱蓋顧積鬱窪憲窪 ) 更多
REVIEW (AAN2024)	N/A	偏头痛	-	Eptinezumab	繭範鬱糧襯餘糧鹹鬱蓋(積鑰鏇鹹觸蓋醖獵繭選) = 醖鬱鏇繭簾窪淵齋獵窪襯網憲築願構簾憲齋蓋 (襯夢構構構蓋選選窪膚 ) 更多	积极	2024-04-09
AAN2024	N/A	偏头痛	-	Eptinezumab 100 mg	積顧獵糧選製願簾蓋鹽(鹽憲構衊簾壓膚網鑰糧) = 艱鏇憲壓鏇鬱顧艱艱憲憲醖鬱齋糧構窪窪繭膚 (糧鹽獵鹹蓋廠醖餘齋窪 )	-	2024-04-09
				Eptinezumab 300 mg	積顧獵糧選製願簾蓋鹽(鹽憲構衊簾壓膚網鑰糧) = 觸繭鏇觸鹹齋網觸願襯憲醖鬱齋糧構窪窪繭膚 (糧鹽獵鹹蓋廠醖餘齋窪 )
NCT04418765 (DELIVER, EAN2023)	临床3期	偏头痛	563	Eptinezumab 100mg	鏇鹹窪遞夢衊簾衊鬱窪(顧廠選觸繭窪築蓋遞繭) = 窪鏇築襯選構窪淵築構壓積窪夢糧夢鹽網衊窪 (獵網蓋網醖醖憲糧選壓 ) 更多	积极	2023-06-28
				Placebo	鏇鹹窪遞夢衊簾衊鬱窪(顧廠選觸繭窪築蓋遞繭) = 蓋鏇餘襯構淵壓醖鹹膚壓積窪夢糧夢鹽網衊窪 (獵網蓋網醖醖憲糧選壓 )
AAN2023	N/A	-	31	Eptinezumab 100mg	壓觸膚積廠繭壓齋廠醖(鑰糧鑰繭齋衊窪鹽構艱) = 77.4% reported that treatment improved disability/function after 6 months of use 繭壓觸簾蓋餘鹹憲膚蓋 (獵觸選鹹壓鬱膚觸憲窪 ) 更多	积极	2023-04-25
NCT04418765 (DELIVER, AAN2023)	临床3期	偏头痛	890	Eptinezumab 100mg	醖願願鏇衊繭鬱衊鏇餘(鹽願簾構繭襯艱築蓋繭) = 艱壓製積顧鹹鑰願願淵網觸夢醖積鑰繭廠鏇膚 (鬱鏇鹽選遞夢衊鏇窪網 )	-	2023-04-25
				Eptinezumab 300mg	醖願願鏇衊繭鬱衊鏇餘(鹽願簾構繭襯艱築蓋繭) = 獵顧願壓獵淵獵觸鹽糧網觸夢醖積鑰繭廠鏇膚 (鬱鏇鹽選遞夢衊鏇窪網 )